A new partnership will provide a 360 degree clinical view for Inflammatory Bowel Disease (IBD) with biomarker integration.
Ampersand Health and Calpro AS, a Svar Life Science company, will integrate the CalproSmart™ Self-Test into Ampersand’s My IBD Care, a behavioural science based digital therapeutic app for people with inflammatory bowel disease (IBD).
The integration will enable patients to initiate the CalproSmart Self-Test from home, and share the results in the app for clinicians to review alongside lifestyle, symptom and wearable data on a single dashboard portal that provides a 360 degree view of a person’s condition. This enables greater patient autonomy and self management, as well as a more accurate view of greater disease progression for clinicians.
Specialising in immune mediated inflammatory diseases (IMIDs), Ampersand Health has seen its My IBD Care used by over 50,000 people, as well as by NHS Trusts across the UK, to transform the long-term management of IBD.
Traditionally people living with complex long-term conditions attend hospital on a scheduled basis for routine review, which means that care does not coincide with a flare or specific clinical need when care and clinical support is most valuable and effective.
In addition to extensive self-management support, Ampersand Health’s digital therapeutic is an interface between clinicians and those living with these conditions, enabling asynchronous communication and remote monitoring. Patients are able to get the right support when they need it most, tackling challenges as soon as they arise rather than waiting for a routine check in.
Based on the self-reported data, clinicians are also directly alerted when a patient may be in need of specific intervention or care, which means that flares can be managed quickly and effectively, often dealing with symptoms before reaching a full flare up.
This has led to 89 per cent fewer A&E admissions, a 33 to 47 per cent increase in healthcare service efficiencies and 85 per cent patient preference compared with traditional models.
The app can be used by a patient independently to help them self-manage through educational resources and courses, or in conjunction with a clinical team if their hospital uses the platform.
The CalproSmart Self-Test is used at home by IBD patients to monitor inflammation status in the bowel. The results are read by an e-health application and are displayed, showing the inflammation level (mg/kg) with traffic light indication for the patient.
Clinicians are directly alerted if a patient needs specific intervention or care, which means that flares can be managed quickly and effectively, often dealing with symptoms before reaching a full flare up.
“Healthcare is becoming an integral part of our everyday lives – regardless of whether we are healthy or ill, young or old. E-Health has in the recent years emerged as a great tool for patients to remain prolonged periods in remission,” says Anne Thjømøe, CEO of Calpro AS.
“This collaboration combines the strengths of our two organisations and will help deliver the future of IBD patient care to both patients and health care professionals. We fundamentally believe collaboration builds better, safer, more individualised care for patients”.
Nader Alaghband, founder & CEO of Ampersand Health said: “This partnership with Calpro marks an important milestone in enabling patients to feel more in control of their condition.
“My IBD Care is the ideal platform for the CalproSmart™ Self-Test, meaning that patients and clinicians can monitor important biomarkers without checking multiple siloed systems to give an accurate view of a person’s symptoms and progress.
“As part of My IBD Care, the CalproSmart Self-Test frees up resources and time in hospitals for clinicians, enabling them to focus on providing care, whilst supporting those living with long term inflammatory conditions to feel empowered, involved and informed.”